Dishman Carbogen Amcis upgrades Swiss sites with Japanese partner to produce ADC linkers. 850L reactors coming to Aarau/Neuland by 2027.
Strategic Expansion Highlights
๐ Focus Area: Antibody-Drug Conjugate (ADC) components
๐จ๐ญ Locations Upgraded:
- Aarau Facility:ย 850L reactors + 0.4m filter dryers (Q1 2027)
- Neuland Facility:ย Matching capacity (Q3 2027)
๐คย Partnership:ย Long-standing Japanese pharma client co-investing
Technology & Capacity Boost
Key Infrastructure Additions
| Equipment | Specification | Purpose |
|---|---|---|
| 850L Reactors | GMP-compliant | Large-scale linker synthesis |
| Agitated Filter Dryers | 0.4m capacity | High-potency API handling |
| Containment Systems | ADC-specific | Safe cytotoxic compound processing |
Market Context
๐ ADC Growth: Global market to reach $28B by 2030 (18% CAGR)
๐ Therapeutic Demand: 12+ FDA-approved ADCs in oncology
๐ฏ๐ต Japan Focus: Major hub for ADC innovation (Daiichi Sankyo, Takeda)
Strategic Implications
For CARBOGEN AMCIS
๐ฌ Niche Leadership: Strengthens position as top-3 global ADC CMO
๐ Supply Chain Security: Dual-site production ensures redundancy
๐ Client Lock-in: Deepens partnership with anchor Japanese innovator
For Indian Parent
๐ฎ๐ณ Dishman Carbogen Benefits:
- Revenue upside from Swiss subsidiary
- Potential tech transfer to Indian facilities
- Enhanced credibility for complex injectables
Investment Timeline
๐๏ธ 2021 Baseline: Bubendorf site extension (Phase 1)
๐ ๏ธ 2025-26: Equipment procurement/installation
๐ญ 2027: Full operational capacity
Leadership Insight
“This co-investment reflects our shared vision to dominate the ADC linker market with Swiss precision.”
โ CARBOGEN AMCIS Management
“Our Swiss sites now offer end-to-end ADC capabilities from payload to conjugation.”
โ Dishman Carbogen Spokesperson
Why This Matters?
๐ฏ Precision Medicine: Supports next-gen cancer therapies
โ๏ธ High-Potency Expertise: Positions Switzerland as ADC hub
๐ค Partnership Model: Blueprint for pharma-CMO collaboration
*Follows 2021 CHF 18M Bubendorf investment. Serves Top-10 pharma companies.* ๐๐ฌ
Haldiramโs Expands Ready-to-Eat Empire with โน662 Crore Noida Facility.